Home > Insider Trading > Filing (0000899243-22-031691)

Filing Details

Accession Number:: 0000899243-22-031691
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-22 16:00:12
Reporting Period:: 2022-09-21

Accepted Time:: 2022-09-22 16:00:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1845337	Day One Biopharmaceuticals Inc.	DAWN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1673237	Papanek Julie Grant	395 Oyster Point Blvd, Suite 217 South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-09-21	607,497	$18.54	8,470,407	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-09-21	6,106	$19.29	8,464,301	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-09-21	1,500,000	$0.00	6,964,301	No	4	J	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	J	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	439,358	Indirect	See Footnote
Common Stock	868	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On September 21, 2022, Canaan XI L.P. distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan Partners XI LLC, the general partner of Canaan XI L.P., representing each such partner's pro rata interest in the shares held by Canaan XI L.P. On the same date, Canaan Partners XI LLC distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Act.
Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
Includes shares received in the distributions described in footnote (4) above.
Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.